Keyphrases
Quality of Life
100%
Common Variable Immunodeficiency
100%
Health Economic Evaluation
100%
Increasing Life Expectancy
100%
Immunoglobulin Replacement Therapy (IgRT)
100%
Quality-adjusted Life Years
57%
Cost-effectiveness
42%
Diagnostic Delay
42%
Cost-utility
28%
Incremental Cost-effectiveness Ratio
28%
Health Economic Model
28%
Incremental Benefits
28%
Sensitivity Analysis
14%
Life Expectancy
14%
Am(III)
14%
Economic Impact
14%
Literature Search
14%
Most Common Form
14%
Adult Patients
14%
Disease Burden
14%
Clinical Efficacy
14%
Delayed Diagnosis
14%
Clinical Benefit
14%
Minimal Treatment
14%
Primary Antibody Deficiency
14%
Bronchiectasis
14%
Timely Treatment
14%
Patient Access
14%
Still Face
14%
Reimbursement
14%
Disability-adjusted Life Years
14%
Immunodeficiency Diseases
14%
Treatment Access
14%
Utility Assessment
14%
Early Initiation
14%
Major Infections
14%
Appropriate Dose
14%
Annual Loss
14%
Simulated Patient
14%
Healthcare Payer
14%
Medicine and Dentistry
Quality of Life
100%
Health Care Cost
100%
Life Expectancy
100%
Immunoglobulin
100%
Common Variable Immunodeficiency
100%
Immunodeficiency
100%
Substitution Therapy
100%
Cost-Effectiveness Analysis
62%
Quality Adjusted Life Year
50%
Diagnostic Delay
37%
Disease Burden
12%
Humoral Immune Deficiency
12%
Bronchiectasis
12%
Infection
12%
Disability Adjusted Life Years
12%
Utility Assessment
12%
Low Drug Dose
12%
Nursing and Health Professions
Life Expectancy
100%
Quality of Life
100%
Immunoglobulin
100%
Common Variable Immunodeficiency
100%
Substitution Therapy
100%
Health Economics
100%
Quality Adjusted Life Year
57%
Cost Effectiveness Analysis
42%
Cost Utility Analysis
28%
Incremental Cost-Effectiveness Ratio
28%
Disease Burden
14%
Infection
14%
Low Drug Dose
14%
Reimbursement
14%
Bronchiectasis
14%
Immune Deficiency
14%
Humoral Immune Deficiency
14%
Disability-Adjusted Life Year
14%
Immunology and Microbiology
Immunodeficiency
100%
Intravenous Immunoglobulin
100%
Common Variable Immunodeficiency
100%
Life Expectancy
100%
Quality Adjusted Life Year
50%
Low Drug Dose
12%
Humoral Immune Deficiency
12%
Disease Burden
12%
Face
12%
Disability-Adjusted Life Year
12%
Pharmacology, Toxicology and Pharmaceutical Science
Life Expectancy
100%
Replacement Therapy
100%
Immunoglobulin
100%
Common Variable Immunodeficiency
100%
Infection
14%
Immune Deficiency
14%
Humoral Immune Deficiency
14%
Bronchiectasis
14%
Diseases
14%